BIOGEN INC.
BIIBAPI behind this page
BIIB Q1 2026 request
Playground key active
/api/financials?ticker=BIIB&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 2,477.8 | 2,431 | +1.9% |
Show Product Lines breakouts |
|||
| Alzheimer's Collaboration | 59.5 | 33 | +80.3% |
| Alzheimer's collaboration revenue | 59.5 | 33 | +80.3% |
| AVONEX | 163.2 | 166.8 | -2.2% |
| AVONEX · Non Us | 54.7 | 58.2 | -6.0% |
| AVONEX · US | 108.5 | 108.6 | -0.1% |
| BENEPALI | 122.1 | 111.3 | +9.7% |
| BENEPALI · Non Us | 122.1 | 111.3 | +9.7% |
| Biosimilars | 182.2 | 180.8 | +0.8% |
| Biosimilars · Non Us | 182.2 | 176.5 | +3.2% |
| Contract manufacturing revenue | 237.2 | 282.3 | -16.0% |
| FLIXABI | 10.5 | 13.1 | -19.8% |
| FLIXABI · Non Us | 10.5 | 13.1 | -19.8% |
| Fumarate | 288.5 | 344.9 | -16.4% |
| Fumarate · Non Us | 103.7 | 188 | -44.8% |
| Fumarate · US | 184.8 | 156.9 | +17.8% |
| IMRALDI | 49.6 | 47.4 | +4.6% |
| IMRALDI · Non Us | 49.6 | 47.4 | +4.6% |
| Interferon | 227.5 | 226.3 | +0.5% |
| Interferon · Non Us | 94.7 | 93.6 | +1.2% |
| Interferon · US | 132.8 | 132.7 | +0.1% |
| MS Product Revenues | 957.5 | 953 | +0.5% |
| MS Product Revenues · Non Us | 398.1 | 462.6 | -13.9% |
| MS Product Revenues · US | 559.4 | 490.4 | +14.1% |
| Other | 55.4 | 29.4 | +88.4% |
| Other · Non Us | 0.1 | 1.3 | -92.3% |
| Other · US | 55.3 | 28.1 | +96.8% |
| PLEGRIDY | 64.3 | 59.5 | +8.1% |
| PLEGRIDY · Non Us | 40 | 35.4 | +13.0% |
| PLEGRIDY · US | 24.3 | 24.1 | +0.8% |
| Product | 1,752.3 | 1,726.5 | +1.5% |
| Product And Service Other | 246.9 | 293.3 | -15.8% |
| Product · Non Us | 913.1 | 972.7 | -6.1% |
| Product · US | 839.2 | 753.8 | +11.3% |
| QALSODY | 32.5 | 15.5 | +109.7% |
| QALSODY · Non Us | 22 | 8 | +175.0% |
| QALSODY · US | 10.5 | 7.5 | +40.0% |
| Rare Disease Product Revenue | 557.2 | 563.3 | -1.1% |
| Rare Disease Product Revenue · Non Us | 332.7 | 332.3 | +0.1% |
| Rare Disease Product Revenue · US | 224.5 | 231 | -2.8% |
| Revenue from anti-CD20 therapeutic programs | 419.1 | 378.2 | +10.8% |
| Royalty | 9.7 | 11 | -11.8% |
| Royalty Attributed To OCREVUS | 317.2 | 288.8 | +9.8% |
| SKYCLARYS | 150.7 | 123.9 | +21.6% |
| SKYCLARYS · Non Us | 78.9 | 54.8 | +44.0% |
| SKYCLARYS · US | 71.8 | 69.1 | +3.9% |
| SPINRAZA | 374 | 423.9 | -11.8% |
| SPINRAZA · Non Us | 231.8 | 269.5 | -14.0% |
| SPINRAZA · US | 142.2 | 154.4 | -7.9% |
| TECFIDERA | 109.5 | 206.1 | -46.9% |
| TECFIDERA · Non Us | 78.1 | 166.3 | -53.0% |
| TECFIDERA · US | 31.4 | 39.8 | -21.1% |
| TYSABRI | 441.5 | 381.5 | +15.7% |
| TYSABRI · Non Us | 199.7 | 180.7 | +10.5% |
| TYSABRI · US | 241.8 | 200.8 | +20.4% |
| VUMERITY | 179 | 138.8 | +29.0% |
| VUMERITY · Non Us | 25.6 | 21.7 | +18.0% |
| VUMERITY · US | 153.4 | 117.1 | +31.0% |
| ZURZUVAE | 55.4 | 27.7 | +100.0% |
| ZURZUVAE · Non Us | 0.1 | — | — |
| ZURZUVAE · US | 55.3 | 27.7 | +99.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,477.8 | 2,431 | +1.9% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -24.3 | 10.9 | -322.9% |
| Cost of Revenue | 661 | 629.3 | +5.0% |
Show Product Lines breakouts |
|||
| Clinical Inventory · Reata Pharmaceuticals, Inc | 56.8 | — | — |
| Product · Reportable Segment | 478.7 | 462.2 | +3.6% |
| Royalty · Reportable Segment | 182.3 | 167.1 | +9.1% |
| Research And Development Expense Excluding Acquired In Process Cost | 539 | 434.1 | +24.2% |
Show Business Segments breakouts |
|||
| Reportable Segment · Early stage programs | 69 | 72.4 | -4.7% |
| Reportable Segment · Late stage programs | 102.5 | 49.4 | +107.5% |
| Reportable Segment · Marketed products | 154.2 | 89.5 | +72.3% |
| Reportable Segment · Research and discovery | 40.5 | 44.3 | -8.6% |
| Reportable Segment · Service Other | 172.8 | 178.5 | -3.2% |
Show Type Of Arrangement breakouts |
|||
| Other research and discovery | 34 | 1 | +3300.0% |
| Research And Development Expense Including Acquired In Process Cost | 34 | 200.7 | -83.1% |
| Selling, General & Administrative | 607.3 | 572.5 | +6.1% |
| Amortization And Impairment Of Acquired Intangible Assets | 136.5 | 111.8 | +22.1% |
| Collaborationprofitlosssharing | 74.2 | 58.1 | +27.7% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Samsung Bioepis | 57.2 | 48 | +19.2% |
Show Type Of Arrangement breakouts |
|||
| Sage Therapeutics | 17 | 10.1 | +68.3% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 20.5 | 9.6 | +113.5% |
| Restructuring Charges | 7.9 | 35.3 | -77.6% |
Show Restructuring Cost And Reserve breakouts |
|||
| Workforce Reductions | 7.9 | 35.3 | -77.6% |
| Other Operating Income Expense Net | 19.7 | 68.4 | -71.2% |
| Total Costs & Expenses | 2,100.1 | 2,119.8 | -0.9% |
| Income Before Taxes | 377.7 | 311.2 | +21.4% |
| Income Tax Expense (Benefit) | 58.2 | 70.7 | -17.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 2.9 | -1.2 | +341.7% |
| Net Income | 319.5 | 240.5 | +32.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 319.5 | 240.5 | +32.8% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -20.7 | 10.3 | -301.0% |
| EPS (Basic) | 2.17 | 1.65 | +31.5% |
| EPS (Diluted) | 2.15 | 1.64 | +31.1% |
| Wtd Avg Shares (Basic) | 147.2 | 146.1 | +0.8% |
| Wtd Avg Shares (Diluted) | 148.4 | 146.6 | +1.2% |
| Operating Expenses (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 0.7 | 0.7 | 0.0% |
| Interest Income | -37.9 | -23.9 | -58.6% |
| Other Non-Operating Income (Expense) | 1.1 | -2.5 | +144.0% |
| Comprehensive Income | 361.3 | 202.2 | +78.7% |
| Other Comprehensive Income | 41.8 | -38.3 | +209.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -0.5 | 0.4 | -225.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 52.6 | -57.8 | +191.0% |
| Accumulated Net Unrealized Investment Gain Loss | -1.8 | — | — |
| Accumulated Translation Adjustment | -8.5 | 19.1 | -144.5% |
| Foreign Currency Transaction Gain Loss Before Tax | 6.5 | -3.8 | +271.1% |
| Interest Expense | 67.6 | 60 | +12.7% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,382.7 | 2,598.3 | +30.2% |
| Available For Sale Securities Debt Securities Current | 900 | — | — |
| Accounts Receivable (Q) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 1,369.2 | 1,602.9 | -14.6% |
| Related Party | 421.2 | 393.6 | +7.0% |
| Inventory | 1,949 | 2,273.9 | -14.3% |
| Other Assets Current | 1,168.3 | 757.3 | +54.3% |
| Total Current Assets | 9,190.4 | 7,626 | +20.5% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 465.6 | — | — |
| Property, Plant & Equipment | 3,017.9 | 3,132.4 | -3.7% |
| Operating Lease Right-of-Use Assets | 251.3 | 346.4 | -27.5% |
| Goodwill | 6,488.7 | — | — |
| Deferred Tax Assets | 238.2 | 307.5 | -22.5% |
| Other Non-Current Assets | 777.5 | 559.1 | +39.1% |
| Total Assets | 29,483.1 | 28,033.1 | +5.2% |
| Intangible Assets | 7,254.5 | 7,777.7 | -6.7% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 9,053.5 | 9,584.6 | -5.5% |
| Current Liabilities | |||
| Taxes Payable Current | 93.6 | 626.1 | -85.1% |
| Accounts Payable | 358.5 | — | — |
| Other Liabilities Current | 2,546.8 | — | — |
| Total Current Liabilities | 2,998.9 | 5,297.4 | -43.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 6,288.5 | 4,548.7 | +38.2% |
| Deferred Tax Liabilities | 483.5 | 133.2 | +263.0% |
| Operating Lease Liabilities | 273.4 | 323.4 | -15.5% |
| Other Non-Current Liabilities | 787.1 | — | — |
| Total Liabilities | 10,831.4 | 11,054.4 | -2.0% |
| Accrued Income Taxes Noncurrent | 174.2 | — | — |
| Stockholders' Equity | |||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 896.7 | 629.9 | +42.4% |
| Accumulated Other Comprehensive Income | -140.2 | — | — |
| Retained Earnings | 20,872.2 | 19,500.3 | +7.0% |
| Treasury Stock Value | -2,977.1 | -2,977.1 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,651.7 | 16,978.7 | +9.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -140.2 | -174.5 | +19.7% |
| Additional Paid In Capital | 896.7 | 629.9 | +42.4% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 20,872.2 | 19,500.3 | +7.0% |
| Treasury Stock Common | -2,977.1 | -2,977.1 | 0.0% |
| Total Liabilities & Equity | 29,483.1 | 28,033.1 | +5.2% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -9.9 | -16.2 | +38.9% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -6.3 | -6.2 | -1.6% |
| Accumulated Net Unrealized Investment Gain Loss | -1.6 | — | — |
| Accumulated Other Comprehensive Income | -140.2 | -174.5 | +19.7% |
| Accumulated Translation Adjustment | -122.4 | -152.1 | +19.5% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 319.5 | 240.5 | +32.8% |
Show Equity Components breakouts |
|||
| Retained Earnings | 319.5 | 240.5 | +32.8% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc · Fair Value Adjustment To Inventory | 107.6 | 51.4 | +109.3% |
| Depreciation & Amortization | 204.4 | 183.2 | +11.6% |
| Inventory Write Down | 4.8 | 7.3 | -34.2% |
| Amortization Of Inventory Step Up | 107.6 | 51.4 | +109.3% |
| Stock-Based Compensation | 84 | 81 | +3.7% |
| Deferred Income Taxes | 23.6 | -27.8 | +184.9% |
| Increase Decrease In Equity Securities Fv Ni | -19 | 40.9 | -146.5% |
| Other Non-Cash Items | 28 | 6.7 | +317.9% |
| Change in Accounts Receivable (Q) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | -33.7 | -181 | +81.4% |
| Related Party | 103.4 | 70.4 | +46.9% |
| Change in Inventory | 116.2 | 62 | +87.4% |
| Increase Decrease In Accrued Liabilities | -243.2 | -300.5 | +19.1% |
| Increase Decrease In Accrued Income Taxes Payable | 18.4 | 69.1 | -73.4% |
| Increase Decrease In Other Operating Capital Net | -89 | -53.5 | -66.4% |
| Net Cash from Operations | 645.5 | 259.3 | +148.9% |
| Investing Activities | |||
| Capital Expenditures | -51.2 | -37.1 | -38.0% |
| Proceeds From Sale And Maturity Of Marketable Securities | 625.2 | — | — |
| Purchases of Investments | -748.8 | — | — |
| Payments To Acquire In Process Research And Development | -35 | — | — |
| Proceeds From Sale Of Other Investments | 0.5 | — | — |
| Other Investing Activities | -0.2 | -0.2 | 0.0% |
| Net Cash from Investing | -209.5 | -47.3 | -342.9% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -55.1 | -24.3 | -126.7% |
| Proceeds From Payments For Other Financing Activities | 11.3 | 1.3 | +769.2% |
| Net Cash from Financing | -43.8 | -23 | -90.4% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 392.2 | 189 | +107.5% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -18 | 34.3 | -152.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.